Initial Experience of Contact Laser Vaporization of the Prostate Using the New Type of Fiber for Benign Prostatic Hyperplasia in a Single Institution.

OBJECTIVES

The objective of this study is to evaluate our initial experience with contact laser vaporization of the prostate (CVP) using the new type of fiber for benign prostatic hyperplasia (BPH).

METHODS

We retrospectively evaluated 43 patients in whom CVP was performed using the new type of fiber from October 2020 to December 2021 at our institution. Total International Prostate Symptom Score (IPSS), IPSS voiding, IPSS storage, IPSS postmicturition, quality of life (QOL) index, maximum urinary flow rate (Qmax), and postvoid residual urine (PVR) were evaluated preoperatively and at 1, 3, 6, and 12 months postoperatively. Prostate volume was assessed preoperatively and at 12 months postoperatively. Complications were also evaluated.

RESULTS

Total IPSS, IPSS voiding, IPSS postmicturition, QOL index, and PVR showed significant improvement at 1 month postoperatively. IPSS storage showed significant improvement at 3 months postoperatively (p = 0.001), and Qmax showed significant improvement at 6 months postoperatively (p = 0.021). The preoperative prostate volume was 87.8 (65.0-116.7) ml and significantly decreased to 80.5 (42.6-97.4) ml at 12 months postoperatively (p = 0.002). The complications were acute prostatitis (9.3%) and temporary urinary retention (7.0%).

CONCLUSION

CVP using the new type of fiber was found to be a minimally invasive surgical procedure. There were no severe complications, and the short-term outcomes were favorable.